eXciteOSA for Treatment of Moderate Obstructive Sleep Apnea (ELMO)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05252156 |
Recruitment Status :
Completed
First Posted : February 23, 2022
Last Update Posted : December 2, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sleep Apnea, Obstructive | Device: eXciteOSA | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 62 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-label Randomized Controlled Trial Assessing the Efficacy of Two Levels of Intraoral Neuromuscular Electrical Stimulation for Moderate Obstructive Sleep Apnea: The ELMO Trial |
Actual Study Start Date : | March 21, 2022 |
Actual Primary Completion Date : | October 26, 2022 |
Actual Study Completion Date : | October 31, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Therapy Dose-A
Neuromuscular electrical stimulation; two 20-minute sessions per day.
|
Device: eXciteOSA
eXciteOSA |
Experimental: Therapy Dose-B
Neuromuscular electrical stimulation; one 30-minute session per day.
|
Device: eXciteOSA
eXciteOSA |
No Intervention: No Therapy
Under the care of the referring physician, with no therapy applied
|
- The difference in the delta-REI (baseline to follow-up) between therapy (Dose-A and Dose-B combined) and no therapy [ Time Frame: Six weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Aged >=18 years;
- Diagnosed with moderate OSA;
- Smartphone or tablet capable of running the eXciteOSA app;
- Fluent in written and spoken English.
Exclusion Criteria:
- BMI >=35 kg/m2;
- Implanted medical device;
- Dental braces and/or intraoral metal jewelry;
- Any condition impacting the tissue of the oral cavity, including but not limited to ulceration or periodontitis;
- Symptomatic nasal pathology such as septal deviation, nasal polyposis, or chronic rhinosinusitis;
- Tonsillar hypertrophy (tonsil size grade 3 or greater);
- Clinically significant facial or oropharyngeal abnormalities such as class 2 malocclusion;
- Prior oropharyngeal surgery for sleep-disordered breathing;
- At-home use of a mandibular advancement device or PAP for sleep-disordered breathing within the previous four weeks;
- Use of any overnight therapy that cannot be withdrawn during study enrollment;
- Diagnosed with any sleep disorder other than OSA;
- Chronic use of central nervous system depressants;
- Driver in a sleepiness-related vehicular accident or near-miss within the two years prior to enrolment (self-report);
- Employed as a commercial driver, pilot, or other occupation that may be impacted by hypersomnolence;
- Considered by the PI to be at risk of an AE resulting from hypersomnolence;
- Any periods of non-connectivity (wifi or cellular data) exceeding 48 hours planned to take place, or likely to take place, during enrollment;
- Current or planned pregnancy;
- Member of a vulnerable population, including but not limited to prisoners and those lacking consent capacity;
- Clinically-significant burden of comorbidities (including history of myocardial infarction, cardiac arrhythmia, heart failure, history of stroke, or transient ischemic attack), and/or any other limitation or condition that may impact the patient's ability to complete the study protocol and use the device per the Instructions for Use (PI discretion);
- Employee and/or residing household member who is an employee of a company that produces or distributes products designed to diagnose, treat, and/or monitor sleep or sleep-disordered breathing (including the Sponsor).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05252156
United States, Alabama | |
Sleep Disorders Center of Alabama | |
Birmingham, Alabama, United States, 35213 | |
United States, Colorado | |
Delta Waves | |
Colorado Springs, Colorado, United States, 80918 | |
United States, Florida | |
Florida Lung & Sleep Associates | |
Lehigh Acres, Florida, United States, 33971 | |
United States, Maryland | |
Pulmonary and Critical Care Associates of Baltimore | |
Baltimore, Maryland, United States, 21286 | |
United States, Missouri | |
Clayton Sleep Institute | |
Saint Louis, Missouri, United States, 63143 | |
United States, Ohio | |
Ohio Sleep Medicine Institute | |
Dublin, Ohio, United States, 43017 | |
United States, South Carolina | |
Bogan Sleep Consultants | |
Columbia, South Carolina, United States, 29201 |
Study Director: | Yasser Zayni | yasser.z@signifiermedical.com |
Responsible Party: | Signifier Medical Technologies |
ClinicalTrials.gov Identifier: | NCT05252156 |
Other Study ID Numbers: |
SMT_EOSA_SZT_0003 |
First Posted: | February 23, 2022 Key Record Dates |
Last Update Posted: | December 2, 2022 |
Last Verified: | December 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | No |
Apnea Sleep Apnea Syndromes Sleep Apnea, Obstructive Respiration Disorders Respiratory Tract Diseases |
Signs and Symptoms, Respiratory Sleep Disorders, Intrinsic Dyssomnias Sleep Wake Disorders Nervous System Diseases |